Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Sees Large Drop in Short Interest

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) was the target of a large decrease in short interest in January. As of January 30th, there was short interest totaling 5,320 shares, a decrease of 64.1% from the January 15th total of 14,838 shares. Based on an average daily volume of 47,571 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 47,571 shares, the short-interest ratio is presently 0.1 days.

Jasper Therapeutics Stock Performance

NASDAQ JSPRW traded down $0.00 during mid-day trading on Friday, reaching $0.02. 32,306 shares of the stock were exchanged, compared to its average volume of 34,165. The business’s 50 day moving average is $0.07 and its 200-day moving average is $0.08. Jasper Therapeutics has a 1 year low of $0.02 and a 1 year high of $0.18.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.

The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells.